Join our Whatsapp Community for Daily Price Sheets and News

Veeda Clinical Research Limited Shares Presentations

Access company and investor presentations

Back to Veeda Clinical Research Limited Shares

Company & Investor Presentations

Access presentation materials and corporate overviews for Veeda Clinical Research Limited Shares

Veeda Clinical Research Limited Shares

Veeda Clinic Overview and Key Details **1. Business Overview** Veeda Clinical Research Ltd., founded in 2004 and headquartered in Ahmedabad, is a leading independent Clinical Research Organization (CRO) in India. Veeda specializes in Bioequivalence (BE) and Bioavailability (BA) studies, clinical trials (Phase I-IV) across therapeutic areas, pharmacovigilance, and data management services, and regulatory consulting for global submissions (USFDA, EMA, ANVISA, etc.). The company operates six clinical research facilities across India with a cumulative capacity of 750+ beds and has a track record of over 4,500 clinical studies, serving clients from North America, Europe, and emerging markets. **2. Investment Rationale** The investment rationale for Veeda includes the rising outsourcing by global pharma companies post-COVID creating a Global CRO Opportunity; Veeda's strong regulatory track record with successful audits by USFDA, EMA, WHO, ANVISA, DCGI, and others; a diversified client base working with top 20 global generic and specialty pharma players; high margins business, as clinical research typically enjoys EBITDA margins of 25-30%; and an IPO pipeline, with a DRHP filed with SEBI in March 2024, with listing likely in FY25. **3. Key Risks** Key risks include Client Concentration Risk due to significant dependence on a few large pharma clients; Regulatory Risk with the stringent regulatory environment, where non-compliance can result in business disruptions; Currency Fluctuation, as majority revenues are USD-denominated, INR appreciation could impact profitability; and competition from global CROs (like Parexel, ICON, IQVIA) and Indian peers. **4. IPO Timeline & Exit Options** The IPO timeline includes a DRHP filed in March 2024 with SEBI. The IPO size is approximately ₹850 Cr., a mix of primary issuance and OFS. The use of funds is earmarked for repayment of debt, expansion of clinical facilities, and inorganic acquisitions. The target IPO timeline is expected in Q3 or Q4 FY25. **5. UnlistedZone View** Veeda Clinical Research is well-placed in India's fast-growing CRO sector. Strong regulatory credentials, global client relationships, and expansion plans make it a promising mid-cap pharma services story. Investors must be mindful of regulatory risks, but the sector tailwinds remain favorable. UnlistedZone assigns a "Strong Accumulate" rating and projects a target valuation post-IPO of ₹4,000 - ₹5,000 Cr. **6. Financials (In Cr.)** The financials are as follows: Revenue for FY21 was 196, FY22 was 288, FY23 was 409 and FY24 was 388. EBITDA for FY21 was 67, FY22 was 62, FY23 was 103 and FY24 was 53. PAT for FY21 was 63, FY22 was 50, FY23 was 42 and FY24 was -0.3. EPS for FY21 was 17.6, FY22 was 9.46, FY23 was 8 and FY24 was -0.04. Note that the FY24 figures are estimates based on available data. **7. Shareholding Pattern** The shareholding pattern is as follows: Others hold 39.65%, Basil Private Limited holds 35.52%, Bondway Investment Inc holds 20.45%, and Sabre Partners AIF Trust holds 4.38%. **8. Valuation Metrics** The last deal price was ₹480/share (28 Apr 2025), implied market cap is ₹3024 Cr., P/E Ratio is N/A, Book Value is 168.67, and P/B Ratio is 2.85x. Valuation metrics are based on available market data and may vary. **9. Disclosures and Data Sources** Source: SEBI DRHP filings, Company website, Market Reports, UnlistedZone internal research.

View Presentation
PDF

Our Blogs

Our blog provides insightful information about unlisted shares, offering a deeper understanding of how these assets work, their potential benefits, and the risks involved. Whether you're new to unlisted shares or looking to expand your knowledge, we cover topics such as investment strategies, valuation methods, market trends, and regulatory aspects. Stay updated with expert tips and guides to navigate the unlisted share market effectively.

FAQ's

What are unlisted shares?

+

Unlisted shares are stocks of companies that are not listed on any stock exchange, meaning they are not publicly traded. These shares are typically available for trade in the private market through brokers, and can offer unique investment opportunities.

How can I buy unlisted shares?

+

You can buy unlisted shares through a broker or platform that specializes in unlisted share transactions. We provide a secure and easy way to purchase unlisted shares from top companies, ensuring a smooth transaction process.

What is the share price of unlisted companies?

+

The share prices of unlisted companies can fluctuate based on various factors like market demand, company performance, and private transactions. You can check the latest share prices for unlisted companies on our website for real-time updates.

Are unlisted shares a good investment?

+

Unlisted shares can offer higher growth potential, as they are typically not subject to the same market volatility as listed shares. However, they come with higher risk due to limited liquidity and availability of information. It's important to research thoroughly and consult experts before investing.

How can I sell unlisted shares?

+

To sell unlisted shares, you can connect with a broker or platform that facilitates the sale of private stocks. We help investors buy and sell unlisted shares with ease, ensuring that your transaction is handled professionally and securely.

What are the risks of investing in unlisted shares?

+

Yes, unlisted shares can eventually be listed on a stock exchange through an Initial Public Offering (IPO). This process allows the company to offer its shares publicly and be traded on major exchanges, potentially increasing liquidity and visibility.

What is the share price of unlisted companies?

+

Gains from unlisted shares are subject to capital gains tax in India. Short-term capital gains (if held for less than 24 months) are taxed at your applicable income tax rate, while long-term capital gains (if held for more than 24 months) are taxed at 20% with indexation benefits. Always consult a tax advisor for precise tax implications.

How do I know the current value of unlisted shares?

+

The value of unlisted shares is typically determined by private transactions, financial reports, and market demand. We provide the latest updates on share prices of unlisted companies, giving you the most accurate valuation available.

Is there a minimum investment amount for unlisted shares?

+

The minimum investment for unlisted shares can vary depending on the company and broker. Generally, the minimum investment is higher than for listed stocks, but we provide detailed information to help you make the best investment decisions.

Can I get a dividend from unlisted shares?

+

Yes, unlisted shares may pay dividends if the company has declared them. However, since these companies may be in their growth stage, dividend payments are not always guaranteed. It's important to check the company's financial health before investing.

How do I know which unlisted shares are worth investing in?

+

It's important to conduct thorough research on the company's financials, management, market potential, and overall business model. You can also seek professional advice from experts to help you choose unlisted shares with strong growth prospects.

Are unlisted shares taxed?

+

Gains from unlisted shares are subject to capital gains tax in India. Short-term capital gains (if held for less than 24 months) are taxed at your applicable income tax rate, while long-term capital gains (if held for more than 24 months) are taxed at 20% with indexation benefits. Always consult a tax advisor for precise tax implications.

WhatsAppContact Us